REDUCTION OF ASTHMA EXACERBATIONS FOLLOWING INITIATION OF SINGLE-INHALER TRIPLE THERAPY WITH FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN US CLINICAL CARE

被引：1
|
作者：
Bogart, Michael
Germain, Guillaume
Laliberte, Francois
Mahendran, Malena
Duh, Mei S.
Dirocco, Kristi
Noorduyn, Stephen G.
Paczkowski, Rosirene
Balkissoon, Ronald C.
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.4209
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：6527A / 6528A
页数：2
相关论文
共 50 条
  • [31] InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use
    Singh, D.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S. J.
    Wise, R. A.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [32] Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
    Brealey, Noushin
    Gupta, Ashutosh
    Renaux, Jessica
    Mehta, Rashmi
    Allen, Ann
    Henderson, Alex
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (09) : 753 - 764
  • [33] InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region
    Wise, R. A.
    Criner, G. J.
    Dransfield, M. T.
    Han, M. K.
    Jones, C. E.
    Lettis, S.
    Martinez, F. J.
    Pascoe, S. J.
    Quasny, H.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [34] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
    Mannino, David
    Bogart, Michael
    Germain, Guillaume
    Huang, Shirley P.
    Ismaila, Afisi S.
    Laliberte, Francois
    Jung, Young
    MacKnight, Sean D.
    Stiegler, Marjorie A.
    Duh, Mei Sheng
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
  • [35] Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects
    Malerba, Mario
    Nardin, Matteo
    Santini, Giuseppe
    Mores, Nadia
    Radaeli, Alessandro
    Montuschi, Paolo
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [36] REAL-WORLD IMPACT OF TRIPLE THERAPY WITH FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL ON ASTHMA CONTROL AMONG US PATIENTS WITH ASTHMA
    Bogart, Michael
    Germain, Guillaume
    Laliberte, Frakois
    Mahendran, Malena
    Duh, Mei S.
    CHEST, 2022, 162 (04) : 1930A - 1931A
  • [37] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [38] INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
    Compton, Chris
    Worsley, Sally
    Midwinter, Dawn
    Ismaila, Afisi
    Beeh, Kai-Michael
    Di Boscio, Valentina
    Kocks, Janwillem
    Marin, Jose M.
    Tabberer, Maggie
    Snowise, Neil G.
    Halpin, David M. G.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [39] Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Wrobleski, Kristin
    Noorduyn, Stephen
    Lee, Lydia
    Igboekwe, Emmeline
    Liu, Meixia
    Veeranki, Phani
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [40] Real-World Effectiveness of Fluticasone Furoate/ Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial
    Beeh, Kai -Michael
    Scheithe, Karl
    Schmutzler, Heike
    Krueger, Saskia
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 205 - 216
12345